A-192621
CAS: 195529-54-5
Rif. 3D-VHA52954
| 25mg | Prezzo su richiesta | ||
| 50mg | Prezzo su richiesta | ||
| 100mg | Prezzo su richiesta |
Informazioni sul prodotto
- (2R,3R,4S)-4-(1,3-Benzodioxol-5-yl)-1-[2-[(2,6-diethylphenyl)amino]-2-oxoethyl]-2-(4-propoxyphenyl)-3-pyrrolidinecarboxylic acid
- 3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1-[2-[(2,6-diethylphenyl)amino]-2-oxoethyl]-2-(4-propoxyphenyl)-, (2R,3R,4S)-
- 3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1-[2-[(2,6-diethylphenyl)amino]-2-oxoethyl]-2-(4-propoxyphenyl)-, [2R-(2α,3β,4α)]-
- 3-Pyrrolidinecarboxylicacid,4-(1,3-benzodioxol-5-yl)-1-[2-[(2,6-diethylphenyl)amino]-2-oxoethyl]-2-(4-propoxyphenyl)-,[2R-(2a,3b,4a)]-
- A 192621
- A 192621.1
A-192621 is a new drug that inhibits the activity of angiotensin II type 1 (AT1) receptors. This drug has been shown to significantly reduce systolic blood pressure in rats and to decrease cardiac hypertrophy in mice. A-192621 also reduces the glomerular filtration rate, which may be due to its ability to inhibit tubulointerstitial injury. The pharmacokinetic properties of this drug have been studied in detail and it has been shown that it can cross the blood-brain barrier and bind to basic fibroblast cells. A-192621 also shows an anti-diabetic effect by specifically inhibiting the production of natriuretic peptides.
Proprietà chimiche
Richiesta tecnica su: 3D-VHA52954 A-192621
Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.
